Moderna's stock dropped despite exceeding Q3 earnings forecasts, possibly due to higher Covid-19 vaccination rates last year. CEO Stéphane Bancel dismissed worries about Robert F. Kennedy Jr. impacting vaccine uptake, affirming Moderna's collaboration with government. U.S.